Regenerating islet-derived family member, 4 modulates multiple receptor tyrosine kinases and mediators of drug resistance in cancer

International Journal of Cancer

Volumn 130, Issue 6, 2012, Pages 1251-1263

  Vanderlaag, Kathryn ^a   Wang, Wei ^a   Fayadat Dilman, Laurence ^a   Wagner, Janet ^a   Bald, Laura ^a   Grein, Jeff ^a   Janatpour, Mary J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Bcl 2; colon cancer; Hsp27; prostate cancer; Reg IV; RTK

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; HEAT SHOCK PROTEIN 27; INSULIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P21; PROTEIN P27; REGENERATING ISLET DERIVED FAMILY MEMBER 4; REGULATOR PROTEIN; SOMATOMEDIN RECEPTOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL CYCLE ARREST; CELL PROLIFERATION; CELL STIMULATION; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALE; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

APOPTOSIS; CELL CYCLE; CELL CYCLE CHECKPOINTS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; EPIDERMAL GROWTH FACTOR; GENE KNOCKDOWN TECHNIQUES; HCT116 CELLS; HEK293 CELLS; HSP27 HEAT-SHOCK PROTEINS; HUMANS; INSULIN; LECTINS, C-TYPE; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; TYROSINE; UP-REGULATION;

EID: 84856119783     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26089     Document Type: Article

References (46)

1. Hanahan D, Weinberg RA,. The hallmarks of cancer. Cell 2000; 100: 57-70. (Pubitemid 30046295)
2. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S,. The protein kinase complement of the human genome. Science 2002; 298: 1912-34. (Pubitemid 35425239)
3. Yarden Y, Sliwkowski MX,. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-37. (Pubitemid 33674041)
4. Siegel-Lakhai WS, Beijnen JH, Schellens JH,. Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa). Oncologist 2005; 10: 579-89. (Pubitemid 41429121)
5. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van HG, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357: 2040-8. (Pubitemid 350106711)
6. Bianco R, Damiano V, Gelardi T, Daniele G, Ciardiello F, Tortora G,. Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling. Curr Pharm Des 2007; 13: 3358-67. (Pubitemid 350201670)
7. Ho MR, Lou YC, Wei SY, Luo SC, Lin WC, Lyu PC, Chen C,. Human RegIV protein adopts a typical C-type lectin fold but binds mannan with two calcium-independent sites. J Mol Biol 2010; 402: 682-95.
8. Zhang YW, Ding LS, Lai MD,. Reg gene family and human diseases. World J Gastroenterol 2003; 9: 2635-41.
9. Hayashi T, Matsubara A, Ohara S, Mita K, Hasegawa Y, Usui T, Arihiro K, Norimura S, Sentani K, Oue N, Yasui W,. Immunohistochemical analysis of Reg IV in urogenital organs: frequent expression of Reg IV in prostate cancer and potential utility as serum tumor marker. Oncol Rep 2009; 21: 95-100.
10. Nakata K, Nagai E, Ohuchida K, Aishima S, Hayashi A, Miyasaka Y, Yu J, Mizumoto K, Tanaka M, Tsuneyoshi M,. REG4 is associated with carcinogenesis in the 'intestinal' pathway of intraductal papillary mucinous neoplasms. Mod Pathol 2009; 22: 460-8.
11. Oue N, Kuniyasu H, Noguchi T, Sentani K, Ito M, Tanaka S, Setoyama T, Sakakura C, Natsugoe S, Yasui W,. Serum concentration of Reg IV in patients with colorectal cancer: overexpression and high serum levels of Reg IV are associated with liver metastasis. Oncology 2007; 72: 371-80. (Pubitemid 351238152)
12. Sasahira T, Oue N, Kirita T, Luo Y, Bhawal UK, Fujii K, Yasui W, Kuniyasu H,. Reg IV expression is associated with cell growth and prognosis of adenoid cystic carcinoma in the salivary gland. Histopathology 2008; 53: 667-75. (Pubitemid 352768720)
13. Ohara S, Oue N, Matsubara A, Mita K, Hasegawa Y, Hayashi T, Usui T, Amatya VJ, Takeshima Y, Kuniyasu H, Yasui W,. Reg IV is an independent prognostic factor for relapse in patients with clinically localized prostate cancer. Cancer Sci 2008; 99: 1570-7.
14. Miyagawa K, Sakakura C, Nakashima S, Yoshikawa T, Kin S, Nakase Y, Fukuda K, Hagiwara A, Okazaki Y, Hayashizaki Y, Yamagishi H,. [Analysis of Reg IV expression in peritoneal dissemination of gastric cancer using real-time RT-PCR]. Gan To Kagaku Ryoho 2005; 32: 1707-8.
15. Mitani Y, Oue N, Matsumura S, Yoshida K, Noguchi T, Ito M, Tanaka S, Kuniyasu H, Kamata N, Yasui W,. Reg IV is a serum biomarker for gastric cancer patients and predicts response to 5-fluorouracil-based chemotherapy. Oncogene 2007; 26: 4383-93. (Pubitemid 47014457)
16. Takehara A, Eguchi H, Ohigashi H, Ishikawa O, Kasugai T, Hosokawa M, Katagiri T, Nakamura Y, Nakagawa H,. Novel tumor marker REG4 detected in serum of patients with resectable pancreatic cancer and feasibility for antibody therapy targeting REG4. Cancer Sci 2006; 97: 1191-7. (Pubitemid 44430644)
17. Bishnupuri KS, Luo Q, Sainathan SK, Kikuchi K, Sureban SM, Sabarinathan M, Gross JH, Aden K, May R, Houchen CW, Anant S, Dieckgraefe BK,. Reg IV regulates normal intestinal and colorectal cancer cell susceptibility to radiation-induced apoptosis. Gastroenterology 2010; 138: 616-26, 626.e1-2.
18. Tamura H, Ohtsuka M, Washiro M, Kimura F, Shimizu H, Yoshidome H, Kato A, Seki N, Miyazaki M,. Reg IV expression and clinicopathologic features of gallbladder carcinoma. Hum Pathol 2009; 40: 1686-92.
19. Gu Z, Rubin MA, Yang Y, Deprimo SE, Zhao H, Horvath S, Brooks JD, Loda M, Reiter RE,. Reg IV: a promising marker of hormone refractory metastatic prostate cancer. Clin Cancer Res 2005; 11: 2237-43. (Pubitemid 40490182)
20. Legoffic A, Calvo E, Cano C, Folch-Puy E, Barthet M, Delpero JR, Ferres-Maso M, Dagorn JC, Closa D, Iovanna J,. The reg4 gene, amplified in the early stages of pancreatic cancer development, is a promising therapeutic target. PLoS One 2009; 4: e7495.
21. Eguchi H, Ishikawa O, Ohigashi H, Takahashi H, Yano M, Nishiyama K, Tomita Y, Uehara R, Takehara A, Nakamura Y, Nakagawa H,. Serum REG4 level is a predictive biomarker for the response to preoperative chemoradiotherapy in patients with pancreatic cancer. Pancreas 2009; 38: 791-8.
22. Kuniyasu H, Oue N, Sasahira T, Yi L, Moriwaka Y, Shimomoto T, Fujii K, Ohmori H, Yasui W,. Reg IV enhances peritoneal metastasis in gastric carcinomas. Cell Prolif 2009; 42: 110-21.
23. Bishnupuri KS, Luo Q, Murmu N, Houchen CW, Anant S, Dieckgraefe BK,. Reg IV activates the epidermal growth factor receptor/Akt/AP-1 signaling pathway in colon adenocarcinomas. Gastroenterology 2006; 130: 137-49. (Pubitemid 43049844)
24. Guo Y, Xu J, Li N, Gao F, Huang P,. RegIV potentiates colorectal carcinoma cell migration and invasion via its CRD domain. Cancer Genet Cytogenet 2010; 199: 38-44.
25. Schroder N, Sekhar A, Geffers I, Muller J, Dittrich-Breiholz O, Kracht M, Wedemeyer J, Gossler A,. Identification of mouse genes with highly specific expression patterns in differentiated intestinal epithelium. Gastroenterology 2006; 130: 902-7. (Pubitemid 43374537)
26. Rafa L, Dessein AF, Devisme L, Buob D, Truant S, Porchet N, Huet G, Buisine MP, Lesuffleur T,. REG4 acts as a mitogenic, motility and pro-invasive factor for colon cancer cells. Int J Oncol 2010; 36: 689-98.
27. Bishnupuri KS, Luo Q, Korzenik JR, Henderson JO, Houchen CW, Anant S, Dieckgraefe BK,. Dysregulation of Reg gene expression occurs early in gastrointestinal tumorigenesis and regulates anti-apoptotic genes. Cancer Biol Ther 2006; 5: 1714-20.
28. Li FY, Ren XB, Xu EP, Huang Q, Sheng HQ, Lv BJ, Lai MD,. RegIV expression showing specificity to gastrointestinal tract and its potential role in diagnosing digestive tract neuroendocrine tumor. J Zhejiang Univ Sci B 2010; 11: 258-66.
29. Nanakin A, Fukui H, Fujii S, Sekikawa A, Kanda N, Hisatsune H, Seno H, Konda Y, Fujimori T, Chiba T,. Expression of the REG IV gene in ulcerative colitis. Lab Invest 2007; 87: 304-14. (Pubitemid 46353938)
30. Ohara S, Oue N, Matsubara A, Mita K, Hasegawa Y, Hayashi T, Usui T, Amatya VJ, Takeshima Y, Kuniyasu H, Yasui W,. Reg IV is an independent prognostic factor for relapse in patients with clinically localized prostate cancer. Cancer Sci 2008; 99: 1570-7.
31. Eguchi H, Ishikawa O, Ohigashi H, Takahashi H, Yano M, Nishiyama K, Tomita Y, Uehara R, Takehara A, Nakamura Y, Nakagawa H,. Serum REG4 level is a predictive biomarker for the response to preoperative chemoradiotherapy in patients with pancreatic cancer. Pancreas 2009; 38: 791-8.
32. Rafa L, Dessein AF, Devisme L, Buob D, Truant S, Porchet N, Huet G, Buisine MP, Lesuffleur T,. REG4 acts as a mitogenic, motility and pro-invasive factor for colon cancer cells. Int J Oncol 2010; 36: 689-98.
33. Di GE, Barbarino M, Bruzzese F, De LS, Caraglia M, Abbruzzese A, Avallone A, Comella P, Caponigro F, Pepe S, Budillon A,. Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells. J Cell Physiol 2003; 195: 139-50. (Pubitemid 36292768)
34. Heiskala K, Arola J, Heiskala M, Andersson LC,. Expression of Reg IV and Hath1 in neuroendocrine neoplasms. Histol Histopathol 2010; 25: 63-72.
35. Di LG, Tortora G, D'Armiento FP, De RG, Staibano S, Autorino R, D'Armiento M, De LM, De PS, Catalano G, Bianco AR, Ciardiello F,. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 2002; 8: 3438-44. (Pubitemid 35340719)
36. Casa AJ, Dearth RK, Litzenburger BC, Lee AV, Cui X,. The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance. Front Biosci 2008; 13: 3273-87. (Pubitemid 351594682)
37. Rocchi P, So A, Kojima S, Signaevsky M, Beraldi E, Fazli L, Hurtado-Coll A, Yamanaka K, Gleave M,. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res 2004; 64: 6595-602. (Pubitemid 39297919)
38. Riedemann J, Takiguchi M, Sohail M, Macaulay VM,. The EGF receptor interacts with the type 1 IGF receptor and regulates its stability. Biochem Biophys Res Commun 2007; 355: 707-14. (Pubitemid 46330209)
39. Rexer BN, Engelman JA, Arteaga CL,. Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonists. Cell Cycle 2009; 8: 18-22.
40. Sachdev D, Singh R, Fujita-Yamaguchi Y, Yee D,. Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer. Cancer Res 2006; 66: 2391-402.
41. Uzzo RG, Haas NB, Crispen PL, Kolenko VM,. Mechanisms of apoptosis resistance and treatment strategies to overcome them in hormone-refractory prostate cancer. Cancer 2008; 112: 1660-71. (Pubitemid 351536826)
42. Sonpavde G, Hutson TE,. New approaches in hormone refractory prostate cancer. Am J Clin Oncol 2006; 29: 196-201. (Pubitemid 44270963)
43. Chaudhary KS, Abel PD, Lalani EN,. Role of the Bcl-2 gene family in prostate cancer progression and its implications for therapeutic intervention. Environ Health Perspect 1999; 107 (Suppl 1): 49-57. (Pubitemid 29164199)
44. Garrido C, Schmitt E, Cande C, Vahsen N, Parcellier A, Kroemer G,. HSP27 and HSP70: potentially oncogenic apoptosis inhibitors. Cell Cycle 2003; 2: 579-84.
45. Gleave M, Miyake H, Chi K,. Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancer. Cancer Chemother Pharmacol 2005; 56 (Suppl 1): 47-57.
46. Pommery N, Henichart JP,. Involvement of PI3K/Akt pathway in prostate cancer-potential strategies for developing targeted therapies. Mini Rev Med Chem 2005; 5: 1125-32. (Pubitemid 41723569)